FDA approvals are significant milestones for biotech companies, often leading to increased investor confidence and stock price appreciation. The approval to expand the HT-001 clinical trial suggests a positive regulatory view on the drug's potential, which can attract investor interest and potentially improve the company's valuation in the short term.